Business Context and Reporting Period
This Form 6-K is an amendment filed by ImmunoPrecise Antibodies Ltd. (the "Company") on February 3, 2025, for the month of February 2025. The filing serves solely to amend a previous Form 6-K submitted on January 27, 2025, by adding a sentence to the press release (Exhibit 99.1) specifying the current number of common shares issued and outstanding. The Company is a foreign private issuer filing under Form 20-F.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural amendment and does not contain financial statements or performance data.
Material Changes
The only material change disclosed is the update to the Company's share count. The press release now specifies that the Company has 45,765,118 common shares issued and outstanding. No other changes were made to the original report or accompanying exhibits.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, outlook, or discussions of risks and contingencies. The primary purpose is to incorporate the updated share count by reference into the Company's Registration Statements on Form S-8 (File No. 333-256730) and Form F-3 (File Nos. 333-273197 and 333-281312).
Investor Verification Checklist
- Verify the updated common share count of 45,765,118 issued and outstanding.
- Confirm the incorporation of this amendment into the specified Form S-8 and Form F-3 registration statements.
- Note that this filing contains no new financial performance data or operational updates beyond the share count correction.